Abstract PR-07: Efficacy and safety of darolutamide in Black/African American patients from the phase III ARAMIS trial

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

Postgraduate Medicine ◽

10.1080/00325481.2015.1027132 ◽

2015 ◽

Vol 127 (5) ◽

pp. 419-428 ◽

Cited By ~ 2

Author(s):

James Thrasher ◽

David S. Kountz ◽

Susanne Crowe ◽

Hans-Juergen Woerle ◽

Maximilian von Eynatten

Keyword(s):

Type 2 Diabetes ◽

African American ◽

Pooled Analysis ◽

Phase Iii ◽

Efficacy And Safety ◽

Black African ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Phase Iii Trials

Download Full-text

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

Endocrine Practice ◽

10.4158/ep13365.or ◽

2014 ◽

Vol 20 (5) ◽

pp. 412-420 ◽

Cited By ~ 15

Author(s):

James Thrasher ◽

Kristen Daniels ◽

Sanjay Patel ◽

Jacqueline Whetteckey ◽

Hans-Juergen Woerle

Keyword(s):

Type 2 Diabetes ◽

African American ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Black African ◽

Double Blind Placebo

Download Full-text

Efficacy and safety results from AvaALL: an open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo)

Pneumologie ◽

10.1055/s-0037-1619221 ◽

2018 ◽

Vol 72 (S 01) ◽

pp. S39-S40

Author(s):

F Griesinger ◽

J Bennouna ◽

J de Castro Carpeno ◽

AM Dingemans ◽

F Grossi ◽

...

Keyword(s):

Lung Cancer ◽

Standard Of Care ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Treatment Beyond Progression

Download Full-text

Phase III Trial to Evaluate the Efficacy and Safety of JS001 Combined With Axitinib for Advanced Mucosal Melanoma

Case Medical Research ◽

10.31525/ct1-nct03941795 ◽

2019 ◽

Author(s):

Keyword(s):

Mucosal Melanoma ◽

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Phase III Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

Case Medical Research ◽

10.31525/ct1-nct04085601 ◽

2019 ◽

Author(s):

Keyword(s):

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1088946.542079 ◽

2007 ◽

Author(s):

Jonathan Schapiro

Keyword(s):

Phase Iii ◽

Efficacy And Safety ◽

Phase Iii Trial ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955151.793461600 ◽

2012 ◽

Author(s):

Mary Norval

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Mycosis Fungoides ◽

Task Force ◽

Cutaneous Lymphoma ◽

Phase Iii ◽

Efficacy And Safety ◽

Ultraviolet A ◽

Stage Ib ◽

Puva Treatment

Download Full-text